In a report released yesterday, David Cerdan from Kepler Capital maintained a Hold rating on Qiagen (QGEN), with a price target of EUR39.00. The company’s shares closed last Monday at $40.47, close to its 52-week high of $43.16.
Cerdan has an average return of 3.2% when recommending Qiagen.
According to TipRanks.com, Cerdan is ranked #5848 out of 6216 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Qiagen with a $37.06 average price target.
See today’s analyst top recommended stocks >>
Based on Qiagen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $413 million and net profit of $44.93 million. In comparison, last year the company earned revenue of $403 million and had a net profit of $60.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.